US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Blossomhill Therapeutics Inc

19.69

+1.105.92%

Post-market: 20.030.3400+1.73%18:43 EDT

Volume:169.33K

Turnover:3.27M

Market Cap:625.84M

PE:-8.06

High:19.86

Open:18.33

Low:18.27

Close:18.59

52wk High:27.99

52wk Low:15.25

Shares:31.78M

Float Shares:9.38M

Volume Ratio:0.77

T/O Rate:1.81%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.4440

EPS(LYR):-24.8342

ROE:--

ROA:--

PB:-3.58

PE(LYR):-0.79

Loading ...

Overview Company News Filings

BlossomHill Therapeutics Advances Pan-KRAS Inhibitor BH-501284 Toward Q1 2027 IND Filing After Preclinical Data Presentation

BlossomHill Therapeutics price target raised to $40 from $36 at Leerink

Blossomhill Therapeutics Inc : JP Morgan Raises Target Price to $30 from $28

THOMSON REUTERS

BlossomHill Therapeutics Price Target Raised to $40.00/Share from $30.00 by Guggenheim

US Research Roundup-eBay, Sunbelt Rentals, T-Mobile

Blossomhill Therapeutics Inc : Guggenheim Raises Target Price to $40 from $30

THOMSON REUTERS

BlossomHill Therapeutics Q2 Loss Widens

MT Newswires Live

Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share

MT Newswires Live

BlossomHill Therapeutics Q2 EPS $(8.75)

Benzinga Earnings

BlossomHill Net Loss Widens 79.35% to $23.8 Million in Q2 FY26; R&D Expenses Rise 70.78% to $21.4 Million

Blossomhill Therapeutics Reports Second Quarter 2026 Financial Results

THOMSON REUTERS

Blossomhill Therapeutics - Q2 2026 Net Loss $23.80 Mln, $-8.75 Per Share

THOMSON REUTERS

Press Release: BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained

BlossomHill updates BH-30643 lung cancer trial results

BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial

MT Newswires Live

BlossomHill Therapeutics announces updated SOLARA trial data

Blossomhill Therapeutics - to Initiate Global Phase 2 Study for Egfr C797s-Positive Nsclc in Q1 2027

THOMSON REUTERS

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/BLSM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BLSM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","market":"US","secType":"STK","nameCN":"Blossomhill Therapeutics Inc","latestPrice":19.69,"timestamp":1790971200000,"preClose":18.59,"halted":0,"volume":169325,"hourTrading":{"tag":"盘后","latestPrice":20.03,"preClose":19.69,"latestTime":"18:43 EDT","volume":562,"amount":11066.46002,"timestamp":1790981022919,"change":0.34,"changeRate":0.017268,"amplitude":0.017268},"delay":0,"changeRate":0.059171597633136175,"floatShares":9375000,"shares":31784899,"eps":-2.444,"marketStatus":"Post-Mkt","change":1.1,"latestTime":"10-02 19:05:52 EDT","open":18.33,"high":19.86,"low":18.27,"amount":3268739.711575,"amplitude":0.08553,"askPrice":20.07,"askSize":99,"bidPrice":19.27,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.444,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790985600000},"marketStatusCode":4,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":18.59,"preHourTrading":{"tag":"盘前","latestPrice":18.75,"preClose":18.59,"latestTime":"08:10 EDT","volume":152,"amount":2850.7499679999996,"timestamp":1790943053506,"change":0.16,"changeRate":0.008607,"amplitude":0.021517},"postHourTrading":{"tag":"盘后","latestPrice":20.03,"preClose":19.69,"latestTime":"18:43 EDT","volume":562,"amount":11066.46002,"timestamp":1790981022919,"change":0.34,"changeRate":0.017268,"amplitude":0.017268},"volumeRatio":0.774795},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","floatShares":9375000,"roa":"--","roe":"--","lyrEps":-24.834182,"volumeRatio":0.774795,"shares":31784899,"dividePrice":0,"high":19.86,"amplitude":0.08553,"preClose":18.59,"low":18.27,"week52Low":15.25,"pbRate":"-3.58","week52High":27.99,"institutionHeld":0,"latestPrice":19.69,"committee":-0.98,"eps":-2.444,"divideRate":0,"volume":169325,"delay":0,"ttmEps":-2.444,"open":18.33,"prevYearClose":16,"prevWeekClose":19.75,"prevMonthClose":18.64,"prevQuarterClose":18.64,"fiveDayClose":19.75,"twentyDayClose":20.02,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BLSM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BLSM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BLSM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1788926400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BLSM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BLSM","date":"2026-10-01","current":-8.056465,"percent":0.641026,"low":-11.561693,"twenty":-9.482674,"median":-8.079945,"eighty":-6.974089,"high":-2.788792,"avg":-8.178508,"sd":1.555666,"marketCap":592470703},"quantilePoints":[{"date":"2026-08-07","current":-6.897356,"twenty":-6.075643,"median":-4.843074,"eighty":-3.610505,"marketCap":490298560},{"date":"2026-08-14","current":-7.048236,"twenty":-7.038752,"median":-6.897356,"eighty":-6.893907,"marketCap":501023841},{"date":"2026-08-21","current":-6.811139,"twenty":-7.038752,"median":-6.955553,"eighty":-6.893907,"marketCap":484169828},{"date":"2026-08-28","current":-8.535478,"twenty":-7.10945,"median":-6.974951,"eighty":-6.897356,"marketCap":606744468},{"date":"2026-09-04","current":-8.630317,"twenty":-8.140605,"median":-7.054702,"eighty":-6.899943,"marketCap":613486073},{"date":"2026-09-11","current":-9.272633,"twenty":-8.535478,"median":-7.091344,"eighty":-6.910289,"marketCap":659145126},{"date":"2026-09-18","current":-11.561693,"twenty":-9.371783,"median":-7.940581,"eighty":-6.940465,"marketCap":821862961},{"date":"2026-09-25","current":-7.973591,"twenty":-9.483865,"median":-8.079945,"eighty":-6.970641,"marketCap":650637087},{"date":"2026-10-01","current":-7.260759,"twenty":-9.482674,"median":-8.079945,"eighty":-6.974089,"marketCap":592470703}],"updateTime":1790982352622},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BLSM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670239701","title":"BlossomHill Therapeutics Advances Pan-KRAS Inhibitor BH-501284 Toward Q1 2027 IND Filing After Preclinical Data Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2670239701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670239701?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:01","pubTimestamp":1790593277,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics advances pan-KRAS inhibitor BH-501284 toward Q1 2027 IND filing after preclinical data presentationBlossomHill Therapeutics presented preclinical data on BH-501284 at the AACR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL5t9bQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014039.USD","LU2210149790.SGD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","BK4112","IE00B3QW5Z07.USD","BCDF","BK4007","IE00B64PRP62.GBP","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","NDAQ","IE00BN0W2T93.GBP","BK4588","BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014005.SGD","BLSM","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669162281","title":"BlossomHill Therapeutics price target raised to $40 from $36 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2669162281","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669162281?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:20","pubTimestamp":1790007608,"startTime":"0","endTime":"0","summary":"Leerink raised the firm’s price target on BlossomHill Therapeutics (BLSM) to $40 from $36 and keeps an Outperform rating on the shares. Published f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-price-target-raised-to-40-from-36-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-price-target-raised-to-40-from-36-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669904169","title":"Blossomhill Therapeutics Inc : JP Morgan Raises Target Price to $30 from $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2669904169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669904169?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:02","pubTimestamp":1789999370,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D06Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669343166","title":"BlossomHill Therapeutics Price Target Raised to $40.00/Share from $30.00 by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2669343166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669343166?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:07","pubTimestamp":1789996020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLSM/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669155576","title":"US Research Roundup-eBay, Sunbelt Rentals, T-Mobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669155576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669155576?lang=en_us&edition=fundamental","pubTime":"2026-09-21 15:41","pubTimestamp":1789976490,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-eBay, Sunbelt Rentals, T-MobileSept 21 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including eBay, Sunbelt Ren","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4N45D0ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251131958.USD","EWTX","MTZ","TTMX","SRRK","IHAK","PSWD","OKTG","EMLP","OKTX","THNR","BLSM","NBIX","HUBS","CLIX","TTMI","ONLN","OKTA","PAA","HAKY","SUNB","MCHB","GOSS","AIRR","AMRZ","BKH","PAGP","THO","TMUS","FOUR","PKB","IQMX","EBAY","BK4504","AMZA","CL","SPAM","IBRN","STBQ","ARHS","LU2095319765.USD","LU1201861249.SGD","LU2322448957.HKD","MLPA","CDW","AMLP","LU1064131342.USD","BK4528","BUG","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669784131","title":"Blossomhill Therapeutics Inc : Guggenheim Raises Target Price to $40 from $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2669784131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669784131?lang=en_us&edition=fundamental","pubTime":"2026-09-21 11:20","pubTimestamp":1789960813,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D00A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668492872","title":"BlossomHill Therapeutics Q2 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2668492872","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668492872?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:42","pubTimestamp":1789731771,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics  reported a Q2 loss on Friday of $8.75 per share, widening from a loss of $5.51 a year earlier.One analyst polled by FactSet expected a GAAP loss of $0.77.The company did not report any revenue for the quarter.Cash and cash equivalents for the quarter ended June 30 totaled $95.4 million, which, together with proceeds from its recent IPO, should be sufficient to fund operations into Q2 2028, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668400179","title":"Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2668400179","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668400179?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:12","pubTimestamp":1789729967,"startTime":"0","endTime":"0","summary":"Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668798940","title":"BlossomHill Therapeutics Q2 EPS $(8.75)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668798940","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668798940?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:08","pubTimestamp":1789729700,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics (NASDAQ:BLSM) reported quarterly losses of $(8.75) per share. This is a 58.8 percent decrease over losses of $(5.51) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/61864103/blossomhill-therapeutics-q2-eps-8-75","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668940172","title":"BlossomHill Net Loss Widens 79.35% to $23.8 Million in Q2 FY26; R&D Expenses Rise 70.78% to $21.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2668940172","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668940172?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:01","pubTimestamp":1789729260,"startTime":"0","endTime":"0","summary":"BlossomHill net loss widens 79.35% to $23.8 million in Q2 FY26; R&D expenses rise 70.78% to $21.4 millionBlossomHill posted a Q2 2026 net loss of $23.8 million, widening from $13.2 million a year earl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL306CLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BK4588","NDAQ","BK4007","SG9999014013.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","BCDF","SG9999014039.USD","IE00BQXX3D17.EUR","SG9999014005.SGD","BK4112","BK4585","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","LU0314104364.USD","BLSM","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668794092","title":"Blossomhill Therapeutics Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2668794092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668794092?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:00","pubTimestamp":1789729201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUAXG6LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668495940","title":"Blossomhill Therapeutics - Q2 2026 Net Loss $23.80 Mln, $-8.75 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2668495940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668495940?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:00","pubTimestamp":1789729201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUAXG6LB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668404309","title":"Press Release: BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2668404309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668404309?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:00","pubTimestamp":1789729200,"startTime":"0","endTime":"0","summary":"proceeds from the initial public offering  in August 2026. -- Announced the U.S. Food and Drug Administration  granted Fast Track. designation to BH-30643, a macrocyclic OMNI-EGFR inhibitor, for the. treatment of adult patients with advanced or metastatic epidermal growth. after prior treatment with a third-generation EGFR tyrosine kinase. -- Presented preliminary results of BH-30643 from dose escalation and. backfill cohorts in the ongoing Phase 1/2 SOLARA trial in advanced or. metastatic EGFR-mutant NSCLC at the American Society of Clinical Oncology","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","03160","BK4588","IPO","BK4585","BK4555","BK4604","BLSM","BK4007","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667462944","title":"BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2667462944","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667462944?lang=en_us&edition=fundamental","pubTime":"2026-09-16 01:35","pubTimestamp":1789493756,"startTime":"0","endTime":"0","summary":"In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on BlossomHill Therapeutics, Inc., with a price target of $32....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/blossomhill-buy-rating-reiterated-as-bh-30643-data-strengthen-case-for-c797s-focused-path-32-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/blossomhill-buy-rating-reiterated-as-bh-30643-data-strengthen-case-for-c797s-focused-path-32-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667664478","title":"BlossomHill updates BH-30643 lung cancer trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2667664478","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667664478?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:57","pubTimestamp":1789473452,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics, Inc. ( ($BLSM) ) has issued an announcement. On September 15, 2026, BlossomHill Therapeutics reported updated results fro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/blossomhill-updates-bh-30643-lung-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/blossomhill-updates-bh-30643-lung-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667443426","title":"BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667443426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667443426?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:42","pubTimestamp":1789472523,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics  said Tuesday that updated data from the phase 1/2 SOLARA trial of BH-30643 showed a 45% objective response rate and an 88% disease control rate in patients with EGFR C797S-positive non-small cell lung cancer following prior EGFR inhibitor treatment.Among 40 patients, 18 achieved a confirmed or ongoing unconfirmed partial response, while 25 remained on treatment at a median follow-up of 6.9 months, the company said.Among 174 patients treated at expansion doses of 40 mg, 50 mg or 60 mg twice daily, treatment-related dose reductions and discontinuations occurred in 9% and 3% of patients, respectively, BlossomHill said.BlossomHill plans to initiate a global phase 2 study targeting EGFR C797S-positive NSCLC in Q1 2027.Shares of the company were 6.7% higher in Tuesday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667864112","title":"BlossomHill Therapeutics announces updated SOLARA trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2667864112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667864112?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:10","pubTimestamp":1789470625,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics (BLSM) announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancerm or NSCLC,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-announces-updated-solara-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-announces-updated-solara-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641885","title":"Blossomhill Therapeutics - to Initiate Global Phase 2 Study for Egfr C797s-Positive Nsclc in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641885?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:03","pubTimestamp":1789470205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN4570C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667141644","title":"BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667141644","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667141644?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:00","pubTimestamp":1789470000,"startTime":"0","endTime":"0","summary":"45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat popul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/15/3361888/0/en/blossomhill-therapeutics-presents-updated-data-from-ongoing-phase-1-2-solara-trial-demonstrating-encouraging-anti-tumor-activity-of-omni-egfr-inhibitor-bh-30643-in-egfr-c797s-posit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664285564","title":"Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285564","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285564?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:24","pubTimestamp":1788261848,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}